Concerns about the potential of a drug for fatty liver disease cause Intercept to fall.

Published Date: 27 May 2023

The decision by the regulator's advisory panel to postpone an accelerated approval caused worries about the prospects of Intercept's drug to treat a specific form of fatty liver disease, which caused shares of the company to drop by about 16% on Monday.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Certain surgical gestures during prostate removal linked to better sexual function recovery

2.

Study Hints at Survival Benefit With Transplant for Metastatic Lung Cancer

3.

Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis

4.

Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.

5.

Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot